Steven Cohen Bio N Tech Se Transaction History

Point72 Asset Management, L.P.

$36.6 Billion
Q3 2024

A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Bio N Tech Se stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 361,993 shares of BNTX stock, worth $42.3 Million. This represents 0.12% of its overall portfolio holdings.

Number of Shares

361,993

Previous 461,711 21.6%

Holding current value

$42.3 Million

Previous $37.1 Million 15.87%

% of portfolio

0.12%

Previous 0.1%

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$78.36 - $124.66 $7.81 Million - $12.4 Million	-99,718 Reduced 21.6%	361,993 $43 Million
Q2 2024 Aug 14, 2024	BUY	$80.36 - $102.87 $27.4 Million - $35.1 Million	341,311 Added 283.48%	461,711 $37.1 Million
Q1 2024 May 15, 2024	BUY	$88.96 - $112.35 $10.7 Million - $13.5 Million	120,400 New	120,400 $11.1 Million
Q1 2023 May 15, 2023	SELL	$122.57 - $153.67 $37.1 Million - $46.5 Million	-302,600 Closed	0 $0
Q4 2022 Feb 14, 2023	BUY	$118.43 - $186.05 $22.8 Million - $35.8 Million	192,600 Added 175.09%	302,600 $45.5 Million
Q3 2022 Nov 14, 2022	BUY	$127.65 - $183.11 $14 Million - $20.1 Million	110,000 New	110,000 $14.8 Million
Q1 2022 May 16, 2022	SELL	$126.25 - $231.85 $11.2 Million - $20.6 Million	-88,700 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$216.64 - $362.52 $19.2 Million - $32.2 Million	88,700 New	88,700 $22.9 Million

Others Institutions Holding BNTX

# of Institutions

357

Shares Held

38.3M

Call Options Held

2.45M

Put Options Held

2.29M

View Full List

About BioNTech SE

Ticker BNTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 242,684,992
Market Cap $28.4B
Description
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...

More about BNTX

Track Steven Cohen's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.

Account